Search the GHTC website

Global health R&D delivers for Michigan

US government investment in global health R&D has delivered

Amount
$51.9 million
to Michigan research institutions
Jobs
700+ new jobs
for Michigan
Michigan's top USG-funded global health R&D institutions

Michigan's top USG-funded global health R&D institutions

University of Michigan
$26.6 million
Michigan State University
$23.5 million
Wayne State University
$1.4 million
University of Central Michigan
$420 thousand
Michigan industry in global health R&D

Michigan industry in global health R&D

AbbVie
Location(s): Wyandotte
Bayer
Location(s): Muskegon
Emergent Biosolutions
Location(s): Lansing
NanoBio
Location(s): Ann Arbor
Vestaron Corporation
Location(s): Kalamazoo

Michigan's top areas of global health R&D by USG funding

7.4%
HIV/AIDS
32.5%
Malaria
14.8%
Tuberculosis
21%
Diarrheal diseases
13%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
11.2%
Other
Salmonella infections
Global health R&D at work in Michigan

Michigan State University (MSU) researchers are developing a low-cost skin patch that can rapidly and safely detect malaria. Current diagnostics for malaria generally require blood; the patch will render this unnecessary via an array of microneedles that painlessly collect fluid from just beneath the skin’s surface, an area known to contain proteins from the malaria parasite in infected individuals. This sample will then be transferred to a test that would indicate a positive diagnosis with colored lines. The MSU team aims to develop a prototype for preliminary evaluation. Each year, malaria kills almost half a million people, mostly young children in Africa.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Gabe Bienczycki